Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-157 vs Moxifloxacin vs Gatifloxacin in Bacterial Conjunctivitis
NCT02980523Phase 2Completed
- Sponsor
- Laboratorios Sophia
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bpc-157 in bacterial conjunctivitis (BC) (5 arms), sponsored by Laboratorios Sophia. Primary endpoints: Change From Baseline Bacterial Culture at 1 week and Adverse Events at 23 days. Started Mar 2015; status: completed.
02
Drugs
bpc-157
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT02980523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980523.